Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

AlphaBio Completes Trials of Therapy for NSCLC with CNS Metastases

publication date: Aug 25, 2022

Shanghai Alpha Biopharma reported the last patient visit has taken place in its Phase II/III trial of zorifertinib in patients with advanced EGFRm+ non-small cell lung cancer (NSCLC) and CNS metastases. The trial enrolled 492 patients at 55 study sites. In previous clinical and preclinical tests, zorifertinib showed high blood-brain barrier (BBB) penetration, anti-tumor activity in metastatic CNS lesions, overall efficacy in both CNS and extra-cranial diseases, and a safety profile similar to other EGFR-TKI drugs. AlphaBio acquired zorifertinib from AstraZeneca. More details....

Stock Symbol: (NYSE: AZN)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here